Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues on the C-terminus in human JAK2 was used as an immunogen.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
JAK2 is a member of the Janus family (JAK) tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction (1). The JAK family is constitutively associated with cytokine receptors; upon ligand binding, JAK phosphorylates the receptor. JAK also phosphorylates the cytokine receptor on tyrosine (Tyr) residues that serve as docking sites for cytoplasmic signal transducers and activators of transcription (STAT) proteins (2). Activated STATs translocate to the nucleus to mediate gene transcription (1, 3). JAK2 is activated after binding to the following Interleukin receptors: specifically IL-3 and IL-23 (4). It also plays a role in leptin signaling and control of body weight (4). A chromosomal aberration involving JAK2 is found in a form of pre-B acute myeloid leukemia (5).
Related Pathway
Delta-Notch Signaling Pathway
EGFR1 Signaling Pathway
Jak-STAT signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
